April 13, 2021 — The Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium has launched a new project that will establish a common and harmonized methodology to define and measure healing in ulcerative colitis (UC).
January 25, 2021 — The FNIH Biomarkers Consortium “A Novel Total Lesional Automated Computerized Imaging Platform, Biomarker, and Predictive Model for Metastatic Prostate Cancer Project (NiP- Metastatic Prostate Cancer) is an off-shoot of the FNIH Biomarkers Consortium Vol-PACT project that closed December 2020.
Three Questions with Sarcopenia 2 Principal Investigators Dr. Shalender Bhasin and Dr. Peggy Cawthon
September 21, 2020 — The FNIH Biomarkers Consortium Sarcopenia 2 project, Sarcopenia as a Valid Biomarker for Identifying Individuals at Risk of Disability, recently achieved the key milestone of publishing seven articles in The Journal of the American Geriatrics Society and The Journals of Gerontology.
June 8, 2020 — For the sixth year in a row, the Foundation for the National Institutes of Health (FNIH) has earned the top designation of four-star honors from the nation’s largest independent charity evaluator, Charity Navigator. Only 9 percent of charities evaluated by the group have received this highest rating for at least six consecutive years, indicating that the FNIH “outperforms most charities in America.”
June 3, 2020 – The Foundation for the National Institutes of Health (FNIH) has announced a new project that will test whether an antibiotic taken during labor can prevent infections in mothers and newborns in seven low- and middle-income countries. This study will be conducted by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) through their Global Network for Women’s and Children’s Health Research (Global Network) with funding from the Bill & Melinda Gates Foundation.
FNIH Biomarkers Consortium NIMBLE Project Receives FDA Nod to Move Forward in Biomarker Qualification
May 15, 2020 — The FNIH Biomarkers Consortium program Non-Invasive Biomarkers of Metabolic Liver Disease (NIMBLE) has received acceptance from the U.S. Food and Drug Administration (FDA) for its Letter of Intent (LOI). NIMBLE seeks to qualify biomarkers to easily diagnose clinically significant non-alcoholic steatohepatitis, or NASH.
BETHESDA, MD, June 13, 2019 — The Foundation for the National Institutes of Health (FNIH) is proud to announce that President and Executive Director Maria C. Freire, Ph.D., has been named “Executive of the Year” by NonProfit PRO. Each year, the Nonprofit Professionals of the Year Awards celebrate and honor the best and brightest leaders of the not-for-profit sector. Dr. Freire won the “Executive of the Year” Award for leadership of the FNIH over the past six years, which has fueled innovative approaches to biomedical research.